Announcements Trials
Browse Landscape

Phase

Phase 4 7Phase 3 7Phase 2 7Phase 2/3 3Phase 1 2Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Myeloid 1

Conditions

Leukemia, Myeloid, Acute 29Leukemia 8Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 5Leukemia, Erythroblastic, Acute 5Congenital Abnormalities 5Myeloproliferative Disorders 4Leukemia, Megakaryoblastic, Acute 4Recurrence 3Myelodysplastic Syndromes 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Leukemia, Promyelocytic, Acute 2Leukemia, Eosinophilic, Acute 2Leukemia, Biphenotypic, Acute 2Leukemia, Basophilic, Acute 2Neoplasms by Histologic Type 1Neoplasms 1Myelodysplastic-Myeloproliferative Diseases 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Carcinoma, Hepatocellular 1Blast Crisis 1

Interventions

Cyclophosphamide 72Cytarabine 46fludarabine phosphate 45fludarabine 42Vincristine 29Filgrastim 27Peripheral Blood Stem Cell Transplantation 25Methotrexate 25Etoposide 24Dexamethasone 23Melphalan 21Rituximab 20Doxorubicin 19Clofarabine 19Tacrolimus 17Mycophenolic Acid 17Dasatinib 16Bortezomib 15Whole-Body Irradiation 14Vorinostat 14pegaspargase 13Cyclosporine 13Calcium Dobesilate 13Busulfan 13Antilymphocyte Serum 12tanespimycin 10Topotecan 10Stem Cell Transplantation 10Specimen Handling 10Sirolimus 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Precursor Cell Lymphoblastic Leukemia-Lymphoma × Idarubicin × Clear all
NCT02779283 2020-05-26

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

OHSU Knight Cancer Institute

Phase 1 Completed
7 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00331513 2013-09-30

Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes

National Cancer Institute (NCI)

Phase 1 Completed
40 enrolled
LymphoidMyeloidOther hematologic neoplasm

Congenital Abnormalities, Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Promyelocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡